Lantheus Holdings Inc 's Cash & cash equivalent grew by 19 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Lantheus Holdings Inc 's Quick Ratio to 1.77, above Lantheus Holdings Inc average Quick Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry 6 other companies have achieved higher Quick Ratio than Lantheus Holdings Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1675, from total ranking in the first quarter 2026 at 2370.

Explain Quick Ratio?
How much Cash & cash equivalents LNTH�s has?
What are LNTH�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LNTH Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	19.83 %	34.34 %	33.97 %	-55.76 %	6.4 %
Y / Y Cash & cash equivalent Change	-14.7 %	-46.88 %	-60.66 %	-55.91 %	-8.12 %
Quick Ratio MRQ	1.77	1.5	1.07	1.1	2.48
LNTH's Total Ranking	# 1675	# 2370	# 2160	# 1417	# 1087
Seq. Current Liabilities Change	0.75 %	-1.14 %	-2.84 %	23.81 %	12.96 %
Seq. Cash & cash equivalent Change	19 %	38.83 %	-5.99 %	-45.08 %	-25.89 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 7
Healthcare Sector	# 522
Overall Market	# 1494

Quick Ratio Statistics
High	Average	Low
3.78	1.6	0.43
(Mar 31 2025)		(Dec 31 2014)

Financial Statements
Lantheus Holdings Inc 's Current Liabilities	$ 336 Millions	Visit LNTH's Balance sheet
Lantheus Holdings Inc 's Cash & cash equivalent	$ 593 Millions	Visit LNTH's Balance sheet
Source of LNTH's Sales		Visit LNTH's Sales by Geography

Cumulative Lantheus Holdings Inc 's Quick Ratio

LNTH's Quick Ratio for the trailling 12 Months

LNTH Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-13.5 %	-16.15 %	-21.1 %	-23.68 %	80.04 %
Y / Y Cash & cash equivalent TTM Growth	-46.3 %	-44.3 %	-27.02 %	-4.14 %	21.77 %
Quick Ratio TTM	1.36	1.49	1.96	2.6	2.18
Total Ranking TTM	# 961	# 860	# 464	# 572	# 547
Seq. Current Liabilities TTM Growth	4.28 %	7.03 %	7.59 %	-27.96 %	1.09 %
Seq. Cash & cash equivalent TTM Growth	-5.28 %	-18.52 %	-18.9 %	-14.19 %	-1.77 %

Quick ratio ranking by company, industry and sector >> Back to LNTH Financial Strength Comparisons >> Go to Compare LNTH Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $335.68 millions, cumulative Quick Ratio decreased to 1.36 below the Lantheus Holdings Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Lantheus Holdings Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3811.

Explain Quick Ratio?
How much Cash & cash equivalents LNTH�s has?
What are LNTH�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 887
Within the Market	# 1675

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.26	1.59	0.59
(Mar 31 2024)		(Dec 31 2015)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Qc Technologies Inc	3.00	$ 10.987 Millions	$ 3.669 Millions
Alpha Teknova Inc	2.54	$ 17.436 Millions	$ 6.872 Millions
Lantheus Holdings Inc	1.77	$ 593.298 Millions	$ 335.677 Millions
Insight Molecular Diagnostics Inc	1.73	$ 17.756 Millions	$ 10.286 Millions
Achieve Life Sciences Inc	1.65	$ 326.645 Millions	$ 197.657 Millions
Immucell Corporation	1.51	$ 8.860 Millions	$ 5.863 Millions
Myriad Genetics Inc	0.88	$ 115.200 Millions	$ 130.700 Millions
Biomerica Inc	0.53	$ 1.308 Millions	$ 2.481 Millions

Date modified: 2026-09-18T17:19:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.